O'Reilly logo

Preventing and Treating Missing Data in Longitudinal Clinical Trials by Craig Mallinckrodt

Stay ahead with the world's most comprehensive technology and business learning platform.

With Safari, you learn the way you learn best. Get unlimited access to videos, live online training, learning paths, books, tutorials, and more.

Start Free Trial

No credit card required

1 Why Missing Data Matter

The evidence to support new medicines, devices, or other medical interventions is based primarily on randomized clinical trials. Many of these trials involve assessments taken at the start of treatment (baseline), followed by assessments taken repeatedly during and in some scenarios after the treatment period. In some cases, such as cancer trials, the primary post-baseline assessments are whether or not some important event occurred during the assessment intervals. These outcomes can be summarized by expressing the multiple post-baseline outcomes as a time to an event, or as a percentage of patients experiencing the event at or before some landmark time point. Alternatively, the multiple post-baseline assessments can ...

With Safari, you learn the way you learn best. Get unlimited access to videos, live online training, learning paths, books, interactive tutorials, and more.

Start Free Trial

No credit card required